Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma

Authors
Category Primary study
JournalEuropean Journal of Cancer
Year 2015
This article has no abstract
Epistemonikos ID: 1a0a1294941795670a924e5d70f05837f4f48e8b
First added on: Feb 07, 2025